KR20070059161A - 도파민 수용체 효능제를 함유하는 장시간 작용 서방성 제제및 그 제조방법 - Google Patents

도파민 수용체 효능제를 함유하는 장시간 작용 서방성 제제및 그 제조방법 Download PDF

Info

Publication number
KR20070059161A
KR20070059161A KR1020077008896A KR20077008896A KR20070059161A KR 20070059161 A KR20070059161 A KR 20070059161A KR 1020077008896 A KR1020077008896 A KR 1020077008896A KR 20077008896 A KR20077008896 A KR 20077008896A KR 20070059161 A KR20070059161 A KR 20070059161A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
dopamine receptor
acid
receptor agonist
rotigotine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077008896A
Other languages
English (en)
Korean (ko)
Inventor
루핑 장
Original Assignee
산동 루예 파마슈티칼 컴파니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 산동 루예 파마슈티칼 컴파니 리미티드 filed Critical 산동 루예 파마슈티칼 컴파니 리미티드
Publication of KR20070059161A publication Critical patent/KR20070059161A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020077008896A 2004-09-21 2005-09-21 도파민 수용체 효능제를 함유하는 장시간 작용 서방성 제제및 그 제조방법 Ceased KR20070059161A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200410077961.9 2004-09-21
CN200410077961 2004-09-21

Publications (1)

Publication Number Publication Date
KR20070059161A true KR20070059161A (ko) 2007-06-11

Family

ID=36089849

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077008896A Ceased KR20070059161A (ko) 2004-09-21 2005-09-21 도파민 수용체 효능제를 함유하는 장시간 작용 서방성 제제및 그 제조방법

Country Status (9)

Country Link
US (2) US8691277B2 (enExample)
EP (1) EP1797871B1 (enExample)
JP (1) JP5081622B2 (enExample)
KR (1) KR20070059161A (enExample)
AU (1) AU2005287743B2 (enExample)
CA (1) CA2581143C (enExample)
ES (1) ES2536460T3 (enExample)
PL (1) PL1797871T3 (enExample)
WO (1) WO2006032202A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101481643B1 (ko) * 2010-11-25 2015-01-12 산동 루예 파마슈티칼 컴파니 리미티드 로티고틴, 이의 유도체 또는 로티고틴 또는 이의 유도체의 약제학적으로 허용가능한 염의 조성물
WO2021133051A1 (ko) * 2019-12-23 2021-07-01 환인제약 주식회사 로피니롤을 포함하는 마이크로스피어 및 이를 함유하는 주사제 조성물

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435738B2 (en) 2003-08-18 2008-10-14 Solvay Pharmaceuticals, Inc. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7405216B2 (en) 2004-08-18 2008-07-29 Solvay Pharmaceuticals, B.V. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7964604B2 (en) 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
US7423040B2 (en) 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
US8475829B2 (en) * 2006-04-06 2013-07-02 Nupathe Inc. Implants for the treatment of dopamine associated states
US7786126B2 (en) 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist
CA2654719A1 (en) * 2006-06-16 2007-12-21 Solvay Pharmaceuticals B.V. Combination preparations comprising slv308 and a l-dopa
US8106056B2 (en) 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
TWI392670B (zh) 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
WO2008009665A1 (en) * 2006-07-19 2008-01-24 Boehringer Ingelheim International Gmbh Treatment of pain
US20090304794A1 (en) * 2008-06-09 2009-12-10 Supernus Pharmaceuticals, Inc. Controlled release formulations of pramipexole
EP2452677A1 (en) 2008-09-29 2012-05-16 Wockhardt Limited Extended release dosage form of ropinirole
FR2936710B1 (fr) * 2008-10-07 2011-01-07 Ceva Sante Animale Composition veterinaire antiprolactinique destinee aux ruminants
AU2010266285A1 (en) * 2009-07-02 2012-02-09 Supernus Pharmaceuticals, Inc. A method of treatment of a neurological disorder
WO2011012721A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Carrier linked pramipexole prodrugs
WO2011012723A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Injectable sustained release compositions comprising a pramipexole prodrug
DE102010014113A1 (de) * 2010-04-07 2011-10-13 Acino Ag Freisetzungsverfahren für Implantate
EA201300607A8 (ru) * 2010-12-02 2014-02-28 Ратиофарм Гмбх Ионная жидкость ротиготина
US9956201B2 (en) 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
WO2018096560A1 (en) 2016-11-23 2018-05-31 Cipla Limited Long acting depot formulation for the continuous dopaminergic stimulation
WO2019234069A1 (en) 2018-06-08 2019-12-12 Boehringer Ingelheim Vetmedica Gmbh Liquid pharmaceutical compositions comprising pergolide

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166800A (en) * 1977-08-25 1979-09-04 Sandoz, Inc. Processes for preparation of microspheres
JP2651320B2 (ja) 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法
DE69734060T2 (de) * 1996-05-24 2006-06-29 Angiotech Pharmaceuticals, Inc., Vancouver Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
EP0930874A2 (en) 1996-10-09 1999-07-28 Takeda Chemical Industries, Ltd. A method for producing a microparticle
JPH10167968A (ja) * 1996-10-09 1998-06-23 Takeda Chem Ind Ltd マイクロパーティクルの製造法
PT949905E (pt) * 1996-12-20 2001-12-28 Alza Corp Composicao de gel injectavel de efeito retardado e processo para a sua preparacao
JP3663271B2 (ja) * 1997-01-24 2005-06-22 シュバルツ ファルマ アクチェンゲゼルシャフト 新規の分枝鎖エステル及びその製法
ATE428371T1 (de) * 1998-07-17 2009-05-15 Pacira Pharmaceuticals Inc Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen
US6455526B1 (en) * 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
MEP19408A (en) * 1998-12-16 2010-06-10 Aventis Pharma Inc Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same
GB9828861D0 (en) * 1998-12-31 1999-02-17 Danbiosyst Uk Compositions
JP4540280B2 (ja) 1999-07-09 2010-09-08 ベーテーエス ホールディング インターナショナル ベー ヴィ 光学走査装置
JP4287613B2 (ja) 2000-04-28 2009-07-01 田辺三菱製薬株式会社 マイクロスフェアの製法
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10055742B4 (de) * 2000-11-10 2006-05-11 Schwarz Pharma Ag Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
KR20040005936A (ko) * 2001-04-26 2004-01-16 컨트롤 딜리버리 시스템즈 인코포레이티드 공동약물을 함유하는 서방 약물 전달 시스템
EP1572154B1 (en) * 2002-11-18 2012-02-01 Rutgers, The State University of New Jersey Medical devices employing novel polymers
EP1610791B1 (en) * 2003-03-31 2011-02-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101481643B1 (ko) * 2010-11-25 2015-01-12 산동 루예 파마슈티칼 컴파니 리미티드 로티고틴, 이의 유도체 또는 로티고틴 또는 이의 유도체의 약제학적으로 허용가능한 염의 조성물
US9265835B2 (en) 2010-11-25 2016-02-23 Shan Dong Luye Pharmaceutical Co., Ltd. Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
WO2021133051A1 (ko) * 2019-12-23 2021-07-01 환인제약 주식회사 로피니롤을 포함하는 마이크로스피어 및 이를 함유하는 주사제 조성물

Also Published As

Publication number Publication date
EP1797871A4 (en) 2012-11-28
WO2006032202A1 (fr) 2006-03-30
CA2581143C (en) 2015-03-31
US20080260846A1 (en) 2008-10-23
US8691277B2 (en) 2014-04-08
ES2536460T3 (es) 2015-05-25
US9220782B2 (en) 2015-12-29
JP2008513524A (ja) 2008-05-01
CA2581143A1 (en) 2006-03-30
JP5081622B2 (ja) 2012-11-28
EP1797871A1 (en) 2007-06-20
HK1107012A1 (en) 2008-03-28
AU2005287743B2 (en) 2011-09-29
EP1797871B1 (en) 2015-02-25
PL1797871T3 (pl) 2015-07-31
AU2005287743A1 (en) 2006-03-30
US20140255488A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
US9220782B2 (en) Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof
EP2982367B1 (en) Pharmaceutical composition for parenteral administration, containing donepezil
US10406161B2 (en) Risperidone sustained release microsphere composition
JP6067803B2 (ja) ロチゴチン、その誘導体、又はロチゴチン若しくはその誘導体の薬学的に許容可能な塩の組成物
US20040266813A1 (en) Injectable sustained-release microspheres of huperzine a compoounds
KR101663560B1 (ko) 균일한 서방출성 미립구의 제조방법
WO2018108163A1 (zh) 一种Talazoparib药物组合物及其应用
KR101663561B1 (ko) 서방출성 미립구의 제조방법
KR20220170782A (ko) 세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 제제 조성물
CN1762495B (zh) 含有多巴胺受体激动剂类药物的长效缓释制剂及其制备工艺
CN117530933B (zh) 一种吡仑帕奈长效缓释微球、制备方法及缓释注射剂
CN102784111A (zh) 一种多巴胺受体激动剂类药物的缓释制剂
US20180177777A1 (en) Formulations for mitigating opioid overdose and methods of making and using the same
CN113226288A (zh) 纳曲酮注射型缓释制剂
HK1107012B (en) Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof
WO2006066509A1 (fr) Préparation microsphérique à libération prolongée injectable de dérivés de 3,3-diphénylpropylamine servant d'antagonistes du récepteur muscarinique
TR2022013222A1 (tr) Naltrekson i̇çeren i̇n si̇tu jel oluşturan çözelti̇ler
HK40047988A (en) Naltrexone injectable sustained release formulation

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070419

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20070601

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20080417

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20090428

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20080417

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20090528

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20090428

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20091230

Appeal identifier: 2009101004855

Request date: 20090528

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20090629

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20090528

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20090116

Patent event code: PB09011R02I

E801 Decision on dismissal of amendment
PE0801 Dismissal of amendment

Patent event code: PE08012E01D

Comment text: Decision on Dismissal of Amendment

Patent event date: 20090709

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20090629

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20090116

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20090528

Effective date: 20091230

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20091230

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20090528

Decision date: 20091230

Appeal identifier: 2009101004855

J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

Patent event date: 20091230

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event code: PJ20011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20101119

Appeal identifier: 2010201001244

Request date: 20100304

J302 Written judgement (patent court)

Free format text: JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20100304

Effective date: 20101119

PJ1302 Judgment (patent court)

Patent event date: 20101125

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20100304

Decision date: 20101119

Appeal identifier: 2010201001244

Appeal kind category: Appeal against decision to decline refusal

J2X2 Appeal (before the supreme court)

Free format text: APPEAL BEFORE THE SUPREME COURT FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2002 Appeal before the supreme court

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event date: 20091230

Patent event code: PJ20021S01I

Request date: 20101210

Appeal identifier: 2010301003561

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20110615

J303 Written judgement (supreme court)

Free format text: JUDGMENT (SUPREME COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20101210

Effective date: 20110615

PJ1303 Judgment (supreme court)

Comment text: Written Judgment (Supreme Court)

Patent event date: 20110617

Patent event code: PJ13031S01D

Decision date: 20110615

Appeal kind category: Appeal against decision to decline refusal

Request date: 20101210

Appeal identifier: 2010301003561